October 31, 2017
Valeant Pharmaceuticals International Inc. will pay $13 million to biotechnology company PDL BioPharma Inc. to settle a lawsuit alleging that Valeant owes more than $20 million in unpaid royalties for sales of diabetes drug Glumetza, PDL BioPharma said Monday.